Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now

Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now·Investor's Business Daily
In this article:

AbbVie could soon pressure Regeneron in eczema treatment, an analyst said Friday as Regeneron stock hit a ceiling at its 200-day line.

Advertisement